Back to search

Poland· PL-100496586

Brivaracetam +pharma

A brivaracetam product containing brivaracetamum, registered in Poland by +pharma arzneimittel GmbH. The same ATC class is registered in 18 of our 19 countries.

ATC N03AX23

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedBrivaracetam +pharmaATCN03AX23REGISTER NO.PL-100496586PACKS LISTED4CHECKEDSeptember 27, 2026

Where it is registered

Brivaracetam is registered in 18 of 19 countries.

Countries holding a registration under ATC N03AX23 (brivaracetam), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 10 of them publish a price we can compare per daily dose

Brivaracetam · ATC N03AX23

18 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of brivaracetam costs, country by country.

Normalised to the WHO defined daily dose (0.1 g), the median price runs from $2.61 in France to $22.97 in Switzerland — a ×8.8 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Brivaracetam · price per daily dose (0.1 g)

USD · FX 28 Sept 2026

  • CH Switzerland$22.97
  • IT Italy$3.99
  • FR France$2.61
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Brivaracetamum
Manufacturer
+pharma arzneimittel GmbH
Country
Poland (PL)
ATC code
N03AX23
ATC class
Brivaracetam
Defined daily dose
0.1 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 4

  • gtin
    05901720141651
  • gtin
    05901720141668
  • gtin
    05901720141811
  • gtin
    05901720141828

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

91 interactions on record for brivaracetam.

Graded by severity as the source publishes them — 63 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Brivaracetam · interactions on record

91 records

  • 63 moderate
  • 28 minor

Most severe, free to view

  • MetoclopramideA03FA01moderate
  • ThiethylperazinA04AB03moderate
  • DiphenhydraminA04AB05moderate
  • DronabinolA04AD10moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Brivaracetam in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All brivaracetam products

Authorised across Europe · EMA

The same active substance is authorised in 26 EEA countries. Names it is sold under:

  • Austria · Abavalex, Brivaracetam Genericon
  • Belgium · Brivaracetam Teva
  • Bulgaria · Abavalex
  • Cyprus · Brivaracetam Accord
  • Czechia · Abavalex, Breluncol
  • Germany · Abavalex, Brivaracetam 1 A Pharma
  • Denmark · Abavalex, Brivaracetam Cipla
  • Spain · Brivaracetam Cinfa, Brivaracetam Combix
  • Finland · Brabela, Brivaracetam Desitin
  • France · Brivaracetam Biogaran, Brivaracetam La Colina
  • United Kingdom (Northern Ireland) · Brivaracetam Alissa, Brivaracetam Altair
  • Greece · Brivaracetam Anabiosis, Brivaracetam Anfarm
  • Croatia · Brivaracetam Accord, Brytyn
  • Hungary · Abavalex, Breluncol
  • Ireland · Brivaracetam Clonmel
  • Iceland · Brivaracetam, Brivaracetam Stada
  • Italy · Brileps, Brivaracetam Amarox
  • Liechtenstein · Briviact
  • Malta · Brivaracetam Anfarm, Brivaracetam Clonmel
  • Netherlands · Brivaracetam, Brivaracetam Amarox
  • Norway · Brivaracetam Desitin, Brivaracetam Glenmark
  • Portugal · Brabela, Brivaracetam Anfarm
  • Romania · Abavalex, Breluncol
  • Sweden · Abavalex, Brivaracetam Amarox
  • Slovenia · Clizay
  • Slovakia · Abavalex, Breluncol

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e01bfe58-e8c2-49b9-8d28-0ada96532b77
GET /v1/drugs/e01bfe58-e8c2-49b9-8d28-0ada96532b77?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "10 mg",
  "packaging": "05901720141651 ¦ Rp ¦ 164747\n20 tabl.\n05901720141668 ¦ Rp ¦ 164748\n60 tabl.\n05901720141811 ¦ Rp ¦ 165987\n14 tabl.\n05901720141828 ¦ Rp ¦ 165988\n56 tabl.",
  "substance": "Brivaracetamum 10 mg",
  "common_name": "Brivaracetamum",
  "pl_product_id": "100496586",
  "pozwolenie_nr": "29370",
  "auth_procedure": "DCP",
  "authorisation_validity": "2030-11-06"
}

See everything about brivaracetam.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.